ArticleFrontiers in neurology
Clinical characteristics and long-term treatment outcomes of patients with new-onset epileptic seizures associated with COVID-19 infection.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the clinical characteristics and approximately two-year treatment outcomes of patients with new-onset epileptic seizures during the acute phase of COVID-19 infection. Methods: A retrospective, single-center cohort study was conducted from December 2022 to June 2023. The patients were categorized into two groups: those with acute encephalopathy (Group 1) and those without (Group 2). Results: This study enrolled a total of 34 patients (15 male and 19 female), with 18 assigned to Group 1 and 16 to Group 2. Patients in Group 2 (median: 32.5 years) were significantly younger than those in Group 1 (median: 60 years; Conclusion: New-onset epileptic seizures associated with COVID-19 generally have a favorable prognosis. A lower proportion of patients developed drug-resistant epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.